RPA49 Antibody

What is RPA49 and why is it important in cellular function?

RPA49 is a subunit of RNA Polymerase I (Pol I), essential for rDNA transcription in mammalian cells. While its yeast ortholog (RPA34.5) is non-essential, the mammalian PAF49 (also known as POLR1E) is critical for cell function. Studies have demonstrated that PAF49 is required for rDNA transcription and cell division, with its degradation inducing nucleolar stress and P53 accumulation . PAF49 functions in complex with another subunit, PAF53, and their interaction is mutually dependent for stability—when PAF49 is degraded, PAF53 is also rapidly lost . This interdependence highlights the structural importance of RPA49 in maintaining the integrity of the RNA Polymerase I complex necessary for ribosomal DNA transcription, a fundamental process for cellular growth and proliferation.

What types of RPA49 antibodies are available for research applications?

Several types of RPA49 antibodies are available for research, primarily polyclonal antibodies derived from rabbit hosts. Commercial options include:

• Rabbit polyclonal antibodies that detect endogenous levels of total RPA49 protein

• Antibodies purified by peptide affinity chromatography using techniques such as SulfoLink™ Coupling Resin

• Antibodies generated against synthesized peptides derived from human RPA49, typically corresponding to regions within the internal amino acids

These antibodies are typically supplied in phosphate-buffered saline containing sodium azide and glycerol for stability and are available in different sizes (e.g., 100μl, 200μl) to accommodate various research needs . Most commercial options are designated for research use only and have been validated for specific applications such as Western blotting (WB) and immunofluorescence/immunocytochemistry (IF/ICC).

What are the common applications of RPA49 antibodies in research?

RPA49 antibodies are utilized in several key research applications:

• Western Blotting (WB): Used at dilutions typically ranging from 1:1000 to 1:3000 to detect RPA49 protein expression in cell and tissue lysates

• Immunofluorescence/Immunocytochemistry (IF/ICC): Applied at dilutions between 1:100 and 1:500 to visualize the cellular localization of RPA49, particularly in nucleolar regions where RNA Polymerase I is active

• ELISA: For quantitative detection of RPA49 protein levels

These applications enable researchers to investigate RPA49's role in RNA Polymerase I function, nucleolar organization, and rDNA transcription regulation. The antibodies have been validated for reactivity with human and mouse RPA49 , making them suitable for comparative studies across these species. When combined with other molecular techniques, RPA49 antibodies provide valuable tools for investigating the fundamental processes of ribosome biogenesis and nucleolar function.

What are the optimal storage and handling conditions for RPA49 antibodies?

RPA49 antibodies require specific storage and handling conditions to maintain their effectiveness:

• Storage Temperature: Most RPA49 antibodies should be stored at -20°C for long-term stability. This temperature prevents protein degradation and preserves antibody activity .

• Buffer Composition: Typical formulations include rabbit IgG in phosphate-buffered saline (pH 7.4) with 150mM NaCl, 0.02% sodium azide, and 50% glycerol. The glycerol prevents freeze-thaw damage, while sodium azide inhibits microbial growth .

• Stability Period: When properly stored, these antibodies remain stable for approximately 12 months from the date of receipt .

• Aliquoting: To minimize freeze-thaw cycles, it's advisable to prepare small working aliquots upon receipt. Each freeze-thaw cycle can potentially reduce antibody effectiveness.

When preparing dilutions for experiments, researchers should use fresh buffers and maintain cold temperatures (4°C) to ensure optimal antibody performance. Additionally, avoiding contamination by using sterile techniques when handling the antibody solutions will help maintain reagent integrity throughout the experimental period.

How should researchers validate the specificity of RPA49 antibodies?

Validating RPA49 antibody specificity is crucial for obtaining reliable experimental results. A comprehensive validation approach includes:

• Positive and Negative Controls:

  • Use cell lines or tissues known to express RPA49 as positive controls

  • Include samples where RPA49 has been knocked down or knocked out (e.g., using the auxin-inducible degron system described in the literature ) as negative controls

• Multiple Detection Methods:

  • Compare results across different techniques (e.g., Western blot, immunofluorescence)

  • Verify that protein size detected in Western blots matches the expected molecular weight of RPA49 (approximately 54 kDa)

• Specificity Tests:

  • Perform peptide competition assays using the immunizing peptide to confirm binding specificity

  • Compare results with other validated RPA49 antibodies to ensure consistent detection patterns

• Cross-reactivity Assessment:

  • Test the antibody across multiple species if working with non-human models

  • Verify minimal cross-reactivity with closely related proteins

Research has shown that commercially available RPA49 antibodies detect endogenous levels of total RPA49 , but comprehensive validation in the specific experimental system being used remains essential for high-quality research outcomes.

What are the optimal dilution ratios for different experimental applications?

Optimal dilution ratios for RPA49 antibodies vary depending on the specific application:

These recommended dilutions serve as starting points and may require optimization based on:

• The specific antibody lot and manufacturer

• Sample type and preparation method

• Detection system sensitivity

• Expression level of RPA49 in the particular cell type or tissue

Researchers should perform a dilution series during initial experiments to determine the optimal concentration that provides the best signal-to-noise ratio. For Western blotting, a gradient of antibody concentrations can help identify the dilution that yields clear specific bands with minimal background. Similarly, for immunofluorescence, titration experiments help balance strong specific staining against background fluorescence .

How can RPA49 antibodies be used to study nucleolar stress and cell cycle regulation?

RPA49 antibodies provide powerful tools for investigating nucleolar stress and cell cycle regulation:

• Nucleolar Stress Pathway Analysis:

  • Studies have shown that auxin-induced degradation of PAF49 (the mammalian ortholog of yeast RPA34.5) induces nucleolar stress and accumulation of P53

  • RPA49 antibodies can be used in immunofluorescence experiments to track nucleolar morphology changes during stress

  • Combined with P53 detection, researchers can correlate RPA49 levels with activation of nucleolar stress pathways

• Cell Cycle Impact Assessment:

  • Research demonstrates that PAF49 is essential for cell proliferation but not necessarily for cell viability

  • Knockdown of PAF49 leads to a reduction in EdU incorporation (indicating reduced DNA synthesis) and cell cycle arrest

  • Using RPA49 antibodies in conjunction with cell cycle markers allows for detailed analysis of how RPA49 depletion affects specific cell cycle phases

• Methodological Approach:

  • Immunofluorescence co-staining of RPA49 and nucleolar markers (e.g., fibrillarin, nucleolin) during various cellular stresses

  • Western blot analysis of RPA49 levels correlated with cell cycle regulators

  • Flow cytometry combining RPA49 antibodies with DNA content analysis to determine cell cycle distribution

Research has revealed that PAF49 knockdown results in a slight decrease in G1 phase cells, an increase in S phase cells, and a small decrease in G2 phase cells after extended treatment, with a significant increase in the S/G1 ratio after 48 hours . These findings suggest that RPA49 plays a crucial role in cell cycle progression, particularly affecting the transition through S phase.

What is known about the structural domains of RPA49 and how can antibodies help investigate their functions?

Research on RPA49 structural domains has revealed critical insights that can be further explored using domain-specific antibodies:

• Key Structural Domains:

  • N-terminal dimerization domain: Essential for interaction with PAF53

  • "Arm" domain: Mediates interaction with PolR1B (A135 in yeast, A127 in mammals)

  • C-terminal region: Less resolved in cryo-EM structures, suggesting intrinsic disorder

• Functional Domain Analysis:

  • Studies using mutant constructs have shown that both the dimerization domain and the arm domain (approximately the first 200 amino acids) are required for rDNA transcription and cell cycle progression

  • The C-terminus that is not resolved in cryo-EM structures appears to be non-essential for these functions

• Antibody-Based Approaches:

  • Domain-specific antibodies can be developed to target different regions of RPA49

  • Immunoprecipitation with these antibodies can reveal domain-specific interaction partners

  • Epitope mapping can correlate antibody binding with functional outcomes

Research has demonstrated that while the yeast and human RPA49 homologs share only approximately 18% sequence identity, their structures show remarkable similarity in cryo-EM studies . The disordered arm of mammalian PAF49 is larger than its yeast counterpart and undergoes post-translational modifications that regulate its association with the polymerase . Using epitope-specific antibodies, researchers can further investigate how these modifications affect RPA49 function in different cellular contexts.

How do interactions between RPA49 and PAF53 affect RNA Polymerase I function, and how can antibodies help elucidate this relationship?

The interaction between RPA49 and PAF53 is critical for RNA Polymerase I function, and antibodies provide valuable tools to investigate this relationship:

• Co-dependent Stability:

  • Research has revealed that knockdown of PAF49 results in the rapid degradation of PAF53, indicating their interdependent stability

  • This co-dependence has evolutionary conservation, as a similar pattern occurs with the yeast orthologs RPA34.5 and RPA49

  • Antibodies against both proteins can be used to monitor their respective levels following perturbation of either partner

• Functional Significance:

  • The dimerization domain of PAF49 alone is insufficient to rescue rDNA transcription and cell cycle progression

  • Both the dimerization domain and the "arm" that mediates interaction with PolR1B are required for function

  • Immunoprecipitation experiments using RPA49 antibodies can help identify additional factors that regulate this interaction

• Methodological Approaches:

  • Co-immunoprecipitation with RPA49 antibodies to isolate intact complexes

  • Sequential immunoprecipitation to identify subcomplexes containing both proteins

  • Proximity ligation assays to visualize RPA49-PAF53 interactions in situ

  • Western blotting to monitor degradation kinetics of both proteins following perturbation

Research has shown that only the first 200 amino acids of mPAF49 (containing both the dimerization domain and the polymerase-binding arm) can efficiently prevent PAF53 degradation in the absence of endogenous PAF49 . Constructs containing only the dimerization domain (amino acids 1-100) fail to bind the polymerase and cannot support rDNA transcription . These findings highlight the dual requirement for PAF49 to both dimerize with PAF53 and bind to the polymerase to maintain functional integrity of the complex.

What common problems might researchers encounter when using RPA49 antibodies, and how can they be resolved?

Researchers working with RPA49 antibodies may encounter several challenges that can be systematically addressed:

• High Background in Western Blots:

  • Problem: Non-specific binding causing multiple bands or smears

  • Solutions:

    • Increase blocking time or concentration (5% BSA or milk in TBST)

    • Try alternative blocking agents (e.g., fish gelatin or commercial blockers)

    • Increase antibody dilution (e.g., from 1:1000 to 1:2000)

    • Include competitive peptides to reduce non-specific binding

    • Perform more stringent washing steps (longer or additional washes)

• Weak or Absent Signal:

  • Problem: Insufficient detection of RPA49

  • Solutions:

    • Decrease antibody dilution (e.g., from 1:3000 to 1:1000)

    • Increase sample concentration or loading amount

    • Extend primary antibody incubation (overnight at 4°C)

    • Check extraction method to ensure RPA49 is effectively solubilized

    • Verify protein transfer efficiency with reversible staining methods

• Inconsistent Results in Immunofluorescence:

  • Problem: Variable staining patterns or intensity

  • Solutions:

    • Optimize fixation method (paraformaldehyde vs. methanol)

    • Try different permeabilization approaches (Triton X-100, saponin, etc.)

    • Test antigen retrieval methods if applicable

    • Increase antibody concentration (dilutions between 1:100-1:500 recommended)

    • Control for cell cycle variations (RPA49 expression may fluctuate)

• Cross-reactivity Issues:

  • Problem: Antibody detecting proteins other than RPA49

  • Solutions:

    • Validate with positive and negative controls (RPA49 knockdown samples)

    • Perform peptide competition assays

    • Try alternative antibodies targeting different epitopes of RPA49

    • Include appropriate controls for secondary antibody specificity

Researchers should document optimization steps systematically and maintain consistent protocols once optimal conditions are established to ensure reproducible results across experiments.

How can researchers effectively use RPA49 antibodies in co-localization studies with other nuclear proteins?

Effective co-localization studies with RPA49 and other nuclear proteins require careful experimental design:

• Antibody Compatibility Planning:

  • Select antibodies raised in different host species to allow simultaneous detection

  • When using multiple rabbit antibodies, consider sequential immunostaining with intermediate blocking steps

  • Verify that secondary antibodies do not cross-react with primaries from different species

• Optimized Sample Preparation:

  • Choose fixation methods that preserve both RPA49 and target protein epitopes

    • Paraformaldehyde (4%) works well for many nuclear proteins

    • Consider dual fixation (e.g., paraformaldehyde followed by methanol) for certain combinations

  • Optimize permeabilization to ensure antibody access to nucleolar structures

  • Use antigen retrieval methods if necessary, but validate that they don't disrupt nuclear architecture

• Advanced Imaging Considerations:

  • Employ high-resolution microscopy techniques (confocal, structured illumination)

  • Use spectral unmixing for fluorophores with overlapping emission spectra

  • Include controls for bleed-through and cross-talk between channels

  • Perform sequential scanning rather than simultaneous acquisition when possible

• Quantitative Co-localization Analysis:

  • Use specialized software (ImageJ with co-localization plugins, CellProfiler, etc.)

  • Calculate Pearson's correlation coefficient or Manders' overlap coefficient

  • Perform intensity correlation analysis to quantify spatial relationships

  • Include appropriate statistical analysis of co-localization metrics

Research has shown that RPA49 localizes primarily to the nucleolus, where RNA Polymerase I is active . When performing co-localization studies, researchers should include controls such as RPA194 (another Pol I subunit) that should show high co-localization with RPA49, as well as controls like RPA43 that remain stable even when RPA49 is depleted .

What are the best practices for using RPA49 antibodies in chromatin immunoprecipitation (ChIP) experiments?

While the provided search results don't specifically mention ChIP applications for RPA49 antibodies, we can provide methodological guidance based on general principles and knowledge about RPA49's role as an RNA Polymerase I subunit:

• Experimental Design Considerations:

  • Target regions: Focus on ribosomal DNA loci, particularly the promoter and transcribed regions

  • Controls: Include both positive (known Pol I-bound regions) and negative controls (regions not expected to bind Pol I)

  • Technical replicates: Perform at least three biological replicates to ensure reproducibility

• Optimization Steps for RPA49 ChIP:

  • Crosslinking: Test different formaldehyde concentrations (1-2%) and times (5-20 min)

  • Sonication: Optimize to achieve chromatin fragments of 200-500bp

  • Antibody amount: Titrate antibody concentration to determine optimal signal-to-noise ratio

  • Washing stringency: Adjust salt concentrations in wash buffers to minimize background

• Validation Approaches:

  • Compare RPA49 ChIP results with ChIP using antibodies against other Pol I subunits (e.g., RPA194)

  • Perform sequential ChIP (Re-ChIP) with RPA49 and PAF53 antibodies to confirm co-occupancy

  • Use RPA49-depleted cells (e.g., auxin-inducible degron system) as negative controls

• Data Analysis Recommendations:

  • Normalize to input DNA and IgG control

  • Use appropriate statistical methods to determine significant binding

  • Compare binding patterns with published Pol I ChIP-seq datasets

  • Correlate with RNA expression data from the same regions

Given that research has shown PAF49 is essential for rDNA transcription , ChIP experiments targeting RPA49 should reveal enrichment at actively transcribed ribosomal DNA genes. The results could provide valuable insights into the dynamics of Pol I complex assembly and the specific role of RPA49 in recruitment or stabilization of the polymerase at target loci.

How might RPA49 antibodies contribute to understanding disease mechanisms related to ribosome biogenesis?

RPA49 antibodies have significant potential to advance our understanding of diseases linked to ribosome biogenesis:

• Cancer Research Applications:

  • Studies have demonstrated that disrupting the interaction between PAF49 and PolR1B inhibits Pol I transcription in both normal and cancer cells, leading to cell cycle arrest in normal cells and cancer cell death

  • RPA49 antibodies can help investigate differential expression or modification of RPA49 in various cancer types

  • Immunohistochemistry with RPA49 antibodies could potentially serve as a biomarker for nucleolar activity in tumor samples

• Ribosomopathies Investigation:

  • Genetic disorders affecting ribosome biogenesis (ribosomopathies) often present with tissue-specific manifestations

  • RPA49 antibodies can help determine if RPA49 expression, localization, or function is altered in these conditions

  • Studies comparing RPA49 status across affected and unaffected tissues could provide insights into tissue-specific vulnerabilities

• Stress Response Mechanisms:

  • Nucleolar stress is a key cellular response to various insults and is linked to P53 activation

  • RPA49 antibodies can track nucleolar reorganization during stress responses

  • Combining RPA49 detection with stress markers could elucidate the temporal dynamics of nucleolar stress pathways

• Methodological Approaches:

  • Tissue microarray analysis of RPA49 expression across disease states

  • Proximity ligation assays to detect altered protein interactions in disease contexts

  • ChIP-seq to map genome-wide changes in RPA49 occupancy associated with disease progression

Research has shown that auxin-induced degradation of PAF49 induces nucleolar stress and P53 accumulation , suggesting that disruption of RPA49 function could be both a cause and consequence of disease states. Understanding these relationships could potentially open new therapeutic avenues targeting ribosome biogenesis in diseases where it is dysregulated.

What emerging technologies might enhance the utility of RPA49 antibodies in research?

Several emerging technologies could significantly enhance the research applications of RPA49 antibodies:

• Advanced Imaging Technologies:

  • Super-resolution microscopy (STORM, PALM, STED) to visualize RPA49 localization within nucleolar subcompartments at nanometer resolution

  • Live-cell imaging with fluorescently tagged nanobodies derived from RPA49 antibodies to track dynamics without fixation

  • Correlative light and electron microscopy (CLEM) to relate RPA49 distribution to ultrastructural features of the nucleolus

• Proximity-Based Proteomics:

  • BioID or APEX2 fusions with RPA49 to identify proteins in its immediate vicinity

  • Antibody-based proximity labeling to map the RPA49 interaction network under various conditions

  • Single-cell proteomics to examine cell-to-cell variability in RPA49 complexes

• Combinatorial Omics Approaches:

  • Cut&Run or CUT&Tag using RPA49 antibodies as alternatives to traditional ChIP with higher sensitivity

  • Multiomics integration correlating RPA49 binding sites with transcriptome, proteome, and metabolome data

  • Spatial transcriptomics combined with RPA49 immunostaining to correlate nucleolar activity with local gene expression

• Therapeutic Development Tools:

  • Antibody-drug conjugates targeting RPA49 for potential cancer therapies

  • Intrabodies derived from RPA49 antibodies to modulate RNA Polymerase I function in living cells

  • Screening platforms using RPA49 antibodies to identify compounds that modulate nucleolar stress pathways

Research has already utilized advanced techniques such as the auxin-inducible degron system to study PAF49 function , demonstrating the value of innovative approaches. This system allowed rapid knockdown of PAF49 within 3 hours, preventing cellular compensation mechanisms that occur with slower knockdown methods like RNAi . Similar technological advances could further enhance our ability to study RPA49 with greater temporal and spatial precision.

How can researchers leverage RPA49 antibodies to investigate cross-talk between RNA polymerase I and other nuclear processes?

RPA49 antibodies provide valuable tools for investigating the intricate relationships between RNA Polymerase I and other nuclear processes:

• Nucleolar-Nucleoplasmic Communication:

  • Immunoprecipitation with RPA49 antibodies followed by mass spectrometry to identify non-canonical interaction partners

  • Proximity ligation assays between RPA49 and components of other nuclear compartments

  • ChIP-seq with RPA49 antibodies to identify potential binding at non-rDNA loci

• Cell Cycle Regulation Connections:

  • Research has demonstrated that PAF49 knockdown affects cell cycle progression, particularly causing accumulation in S phase

  • Synchronized cell populations can be analyzed with RPA49 antibodies to track changes in localization or modification throughout the cell cycle

  • Co-immunoprecipitation experiments can reveal cell cycle-dependent interactions

• DNA Damage Response Integration:

  • Studies can examine RPA49 status following various DNA damaging agents

  • Colocalization analysis between RPA49 and DNA damage markers can reveal spatial relationships

  • Sequential ChIP experiments can determine if Pol I and DNA repair machinery occupy the same genomic regions

• Epigenetic Regulation:

  • Combined ChIP experiments with RPA49 and histone modification antibodies

  • Investigation of potential interactions between RPA49 and chromatin modifiers

  • Analysis of how epigenetic drugs affect RPA49 localization and function

Research has shown that nucleolar stress induced by PAF49 degradation leads to P53 accumulation , suggesting cross-talk between ribosome biogenesis and key cellular stress response pathways. Additionally, the finding that PAF49 is required for both rDNA transcription and normal cell cycle progression indicates potential coordination between these fundamental processes. RPA49 antibodies provide essential tools to dissect these relationships at the molecular level, potentially revealing new regulatory mechanisms and therapeutic targets.